Sunshine Biopharma files draft information statement on potential reverse stock split up to 1-for-20 - SBFM News | RalliesSunshine Biopharma files draft information statement on potential reverse stock split up to 1-for-20
S
SBFM• Potential reverse stock split details
- Sunshine Biopharma shareholders authorized an amendment to permit a reverse stock split of common shares at a ratio up to 1-for-20.
- The board would set the final ratio at a whole number up to 1-for-20, or abandon the split.
- As of Sept. 15, 2026, 4,310,301 common shares were outstanding; the split would cut that to 215,515–2,155,150.
- Fractional shares would be rounded up to the next whole share.
- Outstanding warrants would be adjusted for the split ratio, with per-share exercise prices and share counts recalculated.
